• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Wejo Appoints John Maxwell as Chief Financial Officer

    3/16/21 10:12:00 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AQST alert in real time by email

    MANCHESTER, England & DETROIT--(BUSINESS WIRE)--Wejo, the leader in connected vehicle data, today announced that Chief Financial Officer Barry Nightingale is planning to retire and John Maxwell has been appointed his successor in the role. The changes to the leadership team are effective immediately and come at a time of significant growth for the company, which enables mobility intelligence by 12 billion data points a day from 10.6 million vehicles out of a supply base of 50 million vehicles.

    During his tenure at Wejo, Nightingale helped lead the company from early-stage tech startup to global connected vehicle data leader. This included the $42 million of recent funding to ensure the Wejo team could remain at the forefront of the high growth connected vehicle market. Under his financial leadership, Wejo was named “Fastest Growing Company of the Year” at GP Bullhound’s Northern Tech Awards and established robust finance, legal and compliance teams and processes. Nightingale will continue to advise the company through early 2022.

    “Barry has been a savvy financial leader and sage business counselor through some of our most critical moments of growth, and I’m grateful for all he has done to get Wejo to this inflection point,” said Richard Barlow, founder and CEO of Wejo. “He leaves big shoes for John to fill, but I have every confidence the company will remain on strong financial footing in the months and years ahead under his leadership.”

    Maxwell will report directly to Barlow and work closely with the entire executive team and the Board of Directors as the company enters its next phase of growth. He will be responsible for delivering strong financial results through revenue growth and cost management, capital markets transactions, investor relations and board management. Maxwell will be based in the New York City area.

    Maxwell comes to Wejo with more than 30 years of experience driving financial growth in highly successful start-ups in complex industries including tech and telecom. Most recently, he was CFO of Aquestive Therapeutics (Nasdaq: AQST), a specialty pharmaceutical company with a focus on epilepsy and allergy treatments. During his four-year tenure at the company, he prepared AQST for its IPO, raising $115 million of new equity capital in its 2018 IPO and 2019 follow-on. In addition, Maxwell led a $100 million debt recapitalization and a $125 million royalty monetization transaction at Aquestive. Prior, he was SVP of finance and administration at PanAmSat (NYSE: PA), a global satellite telecommunications business, which he helped take private in a transaction lead by KKR in 2003 and subsequently brought public on the NYSE in 2005. He was also CFO at private equity-backed WIL Research, a contract research organization, which was acquired by Charles River Laboratories in 2016. He started his career at Ernst & Young, and held various senior financial roles at General Signal, ADP, INFONXX and Plainfield Asset Management.

    “Having worked at a variety of high-growth companies where I was responsible for taking financial performance to the next level, I recognize the incredible promise in Wejo,” said Maxwell. “The company is on a trajectory that will not only see major transformation in the organization, but also has potential to change the world for the better—from smarter cars to safer roads and more sustainable cities. I am eager for the great opportunity ahead of me working with a growing, global company in a solid market position with no signs of slowing down.”

    For more on Wejo, please visit their website, www.wejo.com.

    About Wejo

    Wejo is the leader in connected vehicle data, revolutionizing the way we live, work and travel by transforming and interpreting historic and real-time vehicle data. The company enables smarter mobility by organizing trillions of data points from over 10.6 million vehicles and more than 42.3 billion journeys globally, across multiple brands, makes and models, and then standardizing and enhancing those streams of data on a vast scale. Wejo partners with ethical, like-minded companies and organizations to turn that data into insights that unlock value for consumers. With the most comprehensive and trusted data, information and intelligence, Wejo is creating a smarter, safer, more sustainable world for all. Founded in 2014, Wejo employs more than 150 people and has offices in Manchester in the UK and Detroit in the US. For more information, visit: www.wejo.com.

    Get the next $AQST alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AQST

    DatePrice TargetRatingAnalyst
    6/2/2025$7.00Outperform
    Oppenheimer
    12/17/2024$17.00Overweight
    Cantor Fitzgerald
    5/10/2024$8.00Outperform
    Leerink Partners
    4/11/2024$10.00Overweight
    Piper Sandler
    3/28/2024$7.00Outperform
    Raymond James
    More analyst ratings

    $AQST
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for LIBERVANT issued to AQUESTIVE THERAPEUTICS INC

    Submission status for AQUESTIVE THERAPEUTICS INC's drug LIBERVANT (ORIG-1) with active ingredient DIAZEPAM has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218623, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

    4/29/24 7:48:13 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    SEC Filings

    View All

    Aquestive Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)

    8/14/25 9:37:47 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Aquestive Therapeutics Inc.

    424B5 - Aquestive Therapeutics, Inc. (0001398733) (Filer)

    8/14/25 5:29:02 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)

    8/14/25 6:26:15 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $AQST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Oppenheimer resumed coverage on Aquestive Therapeutics with a new price target

    Oppenheimer resumed coverage of Aquestive Therapeutics with a rating of Outperform and set a new price target of $7.00

    6/2/25 8:47:02 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Aquestive Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Aquestive Therapeutics with a rating of Overweight and set a new price target of $17.00

    12/17/24 7:27:23 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Aquestive Therapeutics with a new price target

    Leerink Partners initiated coverage of Aquestive Therapeutics with a rating of Outperform and set a new price target of $8.00

    5/10/24 7:29:48 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock

    WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten offering of 21,250,000 shares of its common stock at an offering price of $4.00 per share. The gross proceeds of the offering to Aquestive, before deducting the underwriting discounts and commissions and other offering expenses payable by Aquestive, are expected to be $85 million. The Company intends to use the net proceeds received from the offering, together with the Compan

    8/14/25 6:28:38 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film

    Anaphylm launch funding of $75 million committed by RTW, subject to FDA approval of Anaphylm and other conditions Strategic financing will further strengthen the Company's balance sheet in advance of potential commercialization of Anaphylm for the emergency treatment of allergic reactions, including anaphylaxis WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a $75 million strategic funding agreement with funds managed by RTW Investments, LP ("RTW"), su

    8/14/25 6:00:30 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

    FDA accepts NDA submission for Anaphylm™; PDUFA date set for January 31, 2026Planning continues for a Q1 2026 U.S. launch of Anaphylm, if approved by the FDACompany accelerates Anaphylm global expansion strategy to Canada and the EUCompany to host investor call on August 12, 2025, at 8:00am ET WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the second quarter ended June 30, 2025, and provided a strategic business update. "The sec

    8/11/25 4:01:00 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Korczynski Sherry was granted 25,000 shares, increasing direct ownership by 16% to 181,858 units (SEC Form 4)

    4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)

    8/15/25 8:41:12 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Kraus Carl N covered exercise/tax liability with 10,819 shares, decreasing direct ownership by 3% to 302,747 units (SEC Form 4)

    4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)

    8/12/25 10:11:01 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Brown Gregory B

    4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)

    6/12/25 2:13:31 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    Leadership Updates

    Live Leadership Updates

    View All

    Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024

    WARREN, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced its expected addition to the broad-market Russell 3000® and Russell 2000® Indexes at the conclusion of the 2024 Russell U.S. indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24, 2024. "We are honored that Aquestive is joining the Russell 3000 Index, which represents the 3,000 largest U.S. public

    6/18/24 8:00:00 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive

    WARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Abigail Jenkins to the Company's Board of Directors, effective April 1, 2024. Ms. Jenkins has two decades of leadership in large and small biotech and pharmaceutical companies, with a focus on commercial launch and corporate strategy roles. "I am very pleased to welcome Abbey to the Aquestive Board of Directors. Her two decades of experience in the commercialization of pharmaceutical p

    4/1/24 8:00:00 AM ET
    $AQST
    $EBS
    $GMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment

    Submitted NDA for Libervant™ (diazepam) Buccal Film for treatment of seizure clusters in patients between two and five years of ageAppointed Carl N. Kraus, M.D. as Chief Medical Officer WARREN, N.J., June 29, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) (the "Company" or "Aquestive"), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today provided an update on recent business developments and announced the appointment of Carl N. Kraus, M.D. as Chief Medical Officer of the Company. NDA Filing for Libervant for Pediatric PopulationAquestive submitted a N

    6/29/23 8:42:55 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    Financials

    Live finance-specific insights

    View All

    Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

    FDA accepts NDA submission for Anaphylm™; PDUFA date set for January 31, 2026Planning continues for a Q1 2026 U.S. launch of Anaphylm, if approved by the FDACompany accelerates Anaphylm global expansion strategy to Canada and the EUCompany to host investor call on August 12, 2025, at 8:00am ET WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the second quarter ended June 30, 2025, and provided a strategic business update. "The sec

    8/11/25 4:01:00 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics to Report Second Quarter 2025 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET

    WARREN, N.J., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the second quarter ended June 30, 2025 and provide an update on recent developments in its business after market close on Monday, August 11, 2025. Management will host a conference call for investors at 8:00 a.m. ET on Tuesday, August 12, 2025. To participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast

    8/4/25 7:00:00 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

    Submitted NDA for Anaphylm™ (epinephrine), the first and only oral sublingual film for patients with severe allergic reactions Advancing commercial readiness efforts with a planned Q1 2026 launch of Anaphylm, subject to FDA approvalCompany to host investor call on May 13, 2025, at 8:00am ET WARREN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the first quarter ended March 31, 2025, and provided a strategic business update. "In the firs

    5/12/25 4:01:00 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aquestive Therapeutics Inc.

    SC 13G/A - Aquestive Therapeutics, Inc. (0001398733) (Subject)

    11/14/24 3:47:19 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aquestive Therapeutics Inc.

    SC 13G - Aquestive Therapeutics, Inc. (0001398733) (Subject)

    4/1/24 6:21:14 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aquestive Therapeutics Inc.

    SC 13G - Aquestive Therapeutics, Inc. (0001398733) (Subject)

    2/14/24 3:24:42 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care